The PAAG regimen significantly improved PFS and response rates in metastatic pancreatic cancer compared to chemotherapy alone ...

Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable ...

The MarketWatch News Department was not involved in the creation of this content. Multiple long-term follow-up studies confirm BRUKINSA's superior efficacy and favorable tolerability versus ibrutinib ...

Please provide your email address to receive an email when new articles are posted on . Results showed longer median PFS and a higher 9-month PFS with ivonescimab than pembrolizumab. Patients with ...

Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...

– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – – Although median overall ...

But is the combination a "viable alternative" to nivolumab and ipilimumab?

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK ...

(BUSINESS WIRE )--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by ...